Compare Kroger Co (KR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Zimmer Biomet Holdings Inc — how do they compare? Kroger Co trades at $61.47 (market cap $36.27B), while Zimmer Biomet Holdings Inc trades at $89.49 (market cap $16.95B). The key difference: Kroger Co is far larger — about 2.1× Zimmer Biomet Holdings Inc's market cap, and Kroger Co pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| KR | ZBH | |
|---|---|---|
Market Cap | $36.27B | $16.95B |
Volume | 8,301,523 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $103.98 |
52-Week Low | $55.53 | $79.58 |
Typical Hold Time | 108 Days | 89 Days |
Enterprise Value | $57.69B | $24.02B |
Dividend Yield | 2.54% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.04, up 3.02% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $147.12B revenue, 14.24% ROE, and consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, while the company demonstrates strong cash flow generation with $5.79B from operations in 2025. Technical indicators show the stock trading near pivot point resistance at $62 with bullish moving average alignment.
Kroger presents a compelling value opportunity with low P/S ratio of 0.26 and 47.7% analyst buy ratings, though near-term risks include integration challenges from the Giant Eagle acquisition and cost pressures. The consensus price target of $70.62 suggests 15.7% upside potential, supported by digital growth initiatives and retail media expansion, but investors should monitor identical sales trends and margin pressures in the competitive grocery sector.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
